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The Trial of Intensified Medical Treatment in Elderly patients with Congestive Heart 
Failure (TIME-CHF) is a key study in field of natriuretic peptide-guided therapy for heart 
failure (HF). In addition, the study design allowed numerous important pre-specified 
and post-hoc analysis. In the present thesis, three specific aspects were addressed: i) 
the interaction between HF and renal failure, ii) the prognostic role of heart rate (HR) 
and its potential implications in different HF populations, and iii) the role of N-terminal-
pro-B-type natriuretic peptide (NT-proBNP)-guided management, in particular its long-
term effects and its role in patients with HF and preserved left ventricular ejection frac-
tion (LVEF; HFpEF). The key results were as follows:  
i) Interaction between HF and renal failure 
•  Not every rise in serum creatinine is prognostically relevant. Only larger changes, i.e. 
a rise by more than 44 µmol/l, are associated with an adverse outcome (Chapter II).  
•  Importantly, the clinical context of such changes is relevant. Worsening renal func-
tion during loop diuretic therapy is a sign of poor prognosis whereas this is not the 
case for similar changes occurring during therapy with spironolactone (Chapter III).  
•  In addition, hyperkalemia was shown to be relatively common in elderly and comor-
bid heart failure patients, and treatment with spironolactone was a strong predictor 
of the incidence of hyperkalemia indicating that close surveillance of serum potassi-
um is required in elderly and comorbid patients with heart failure, in particular dur-
ing treatment with spironolactone (Chapter IV). 
ii) Prognostic role of HR and its potential implications in different HF 
populations  
•  While in younger patients (≤75 years) higher HR was a marker of more advanced 
disease (lower LVEF, higher NT-proBNP) and a significant predictor of death and HF 
hospitalisation also after adjustment for baseline characteristics, this was not the 
case in patients with age >75 years indicating that the prognostic role of HR in HF 
depends on age (Chapter V).  
•  In contrast to patients in sinus rhythm, lower HR rather than higher HR was associ-
ated with poor outcome in patients with HF and atrial fibrillation (Chapter VI). 
•  A very simple HR-related parameter, i.e. the change in HR from the supine to the 
upright position (∆HR) was found to be an independent predictor of prognosis 
(Chapter VII).  
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iii) Role of NT-proBNP-guided management, in particular its long-term 
effects and its role in patients with HFpEF 
•  The beneficial prognostic effect of strategy of NT-proBNP-guided management with 
aggressive up-titration of angiotensin converting enzyme inhibitors, betablockers, 
and mineralocorticoid receptor antagonists over a period of 12 months in younger 
patients with HFrEF was maintained after 18 months (Chapter VIII).  
•  NT-proBNP-guided management had opposite prognostic effects in patients with 
HFrEF and patients with heart failure and preserved ejection fraction: beneficial ef-
fects in HFrEF, and a trend towards worse outcomes in HFpEF patients (Chapter IX).  
 
 
 
  
